COMPASS Pathways (NASDAQ:CMPS) Announces Earnings Results, Beats Expectations By $0.04 EPS

COMPASS Pathways (NASDAQ:CMPS) released its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.04, Zacks reports. During the same quarter last year, the company posted ($0.67) earnings per share.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock traded down $0.01 on Friday, reaching $4.75. 2,081,860 shares of the stock were exchanged, compared to its average volume of 874,967. The company has a current ratio of 12.03, a quick ratio of 12.03 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $324.85 million, a PE ratio of -2.16 and a beta of 2.29. COMPASS Pathways has a 1-year low of $4.05 and a 1-year high of $12.75. The business has a fifty day moving average price of $6.61 and a two-hundred day moving average price of $7.04.

Analysts Set New Price Targets

A number of analysts recently issued reports on CMPS shares. Royal Bank of Canada decreased their target price on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Maxim Group cut their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday. Canaccord Genuity Group decreased their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Finally, HC Wainwright dropped their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.67.

Insider Buying and Selling at COMPASS Pathways

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of COMPASS Pathways stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the sale, the insider now directly owns 6,905,774 shares in the company, valued at $41,779,932.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.25% of the stock is owned by corporate insiders.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.